Roivant Sciences Ltd.
ROIV
$20.81
-$0.06-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -27.60% | -71.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.60% | -71.33% | |||
| Cost of Revenue | 7.61% | 5.19% | |||
| Gross Profit | -8.11% | -9.41% | |||
| SG&A Expenses | 1.02% | -43.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.60% | -24.67% | |||
| Operating Income | -4.85% | 23.70% | |||
| Income Before Tax | 40.93% | -32.61% | |||
| Income Tax Expenses | 50.46% | -90.57% | |||
| Earnings from Continuing Operations | 39.38% | -8.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 3.88% | 10.14% | |||
| Net Income | 49.18% | -8.18% | |||
| EBIT | -4.85% | 23.70% | |||
| EBITDA | -4.93% | 22.26% | |||
| EPS Basic | 49.22% | -12.47% | |||
| Normalized Basic EPS | -16.17% | 24.96% | |||
| EPS Diluted | 48.48% | -12.40% | |||
| Normalized Diluted EPS | -16.17% | 24.96% | |||
| Average Basic Shares Outstanding | 0.10% | -3.82% | |||
| Average Diluted Shares Outstanding | 0.10% | -3.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||